within Pharmacolibrary.Drugs.ATC.N;

model N07XX22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 3.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tofersen is an antisense oligonucleotide designed to reduce the production of superoxide dismutase 1 (SOD1) protein. It is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in patients with SOD1 mutations. Tofersen was granted accelerated approval by the FDA in 2023 for use in this patient population.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with SOD1-ALS following repeated intrathecal administration.</p><h4>References</h4><ol><li><p>Miller, T, et al., &amp; Ferguson, TA (2020). Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for . <i>The New England journal of medicine</i> 383(2) 109–119. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2003715&quot;>10.1056/NEJMoa2003715</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32640130/&quot;>https://pubmed.ncbi.nlm.nih.gov/32640130</a></p></li><li><p>Monine, M, et al., &amp; Nestorov, I (2021). A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. <i>Journal of pharmacokinetics and pharmacodynamics</i> 48(5) 639–654. DOI:<a href=&quot;https://doi.org/10.1007/s10928-021-09761-0&quot;>10.1007/s10928-021-09761-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33991294/&quot;>https://pubmed.ncbi.nlm.nih.gov/33991294</a></p></li><li><p>Ediriweera, GR, et al., &amp; Vine, KL (2025). Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 378 221–235. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2024.11.074&quot;>10.1016/j.jconrel.2024.11.074</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39645085/&quot;>https://pubmed.ncbi.nlm.nih.gov/39645085</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX22;
